UBX 1967
Alternative Names: APG-1197; UBX-1967Latest Information Update: 04 Aug 2025
At a glance
- Originator Ascentage Pharma
- Developer Ascentage Pharma; UNITY Biotechnology
- Class Antiglaucomas; Eye disorder therapies; Senotherapeutics; Small molecules
- Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Age-related macular degeneration; Diabetic macular oedema; Diabetic retinopathy; Glaucoma; Retinal disorders
Most Recent Events
- 01 Aug 2025 Discontinued - Preclinical for Age-related macular degeneration in China (unspecified route) (Ascentage Pharma pipeline, August 2025)
- 01 Aug 2025 Discontinued - Preclinical for Age-related macular degeneration in USA (unspecified route) (UNITY Biotechnology website, August 2025)
- 01 Aug 2025 Discontinued - Preclinical for Diabetic macular oedema in China (unspecified route) (Ascentage Pharma pipeline, August 2025)